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Nuclear spindles pave the way to metastasis
Patrick J. Hensley and Natasha Kyprianou
Compelling functional studies link nucleolar and
spindle associated protein 1 (NUSAP1) with prostate
cancer progression to metastasis; the findings highlight a
new value of NUSAP1 as a biomarker of tumor recurrence
and therapeutic targeting in pre-clinical models of
advanced prostate cancer.
Prostate cancer accounted for an estimated 26,120
deaths in the United States in 2016. The majority of these
deaths occur in patients with metastatic castration-resistant
prostate cancer (CRPC) [1]. The recognized architectural
and genomic heterogeneity of prostate tumors and the
persistent activation of the androgen receptor (AR)
signaling are primarily responsible for treatment failure
and clinical relapse [2]. Decision-making regarding the
management of localized disease and identification of
occult, subclinical metastasis must rely on staging and
biomarker validation. Identification of new biomarkers
to predict prostate cancer progression to metastasis and
molecular signatures to define therapeutic resistance
among patients with CRPC is an immediate and critical
need in order to eradicate lethal disease.
Nucleolar and spindle associated protein 1
(NUSAP1) has been previously identified as a prognostic
biomarker in early stage prostate cancer [3]. In the recent
issue of Oncotarget, Gordon and colleagues interrogated
the role of NUSAP1 in prostate cancer progression,
using pre-clinical models and human prostate cancer
specimens [4]. Functional studies indicate that NUSAP1
promotes invasive and metastatic properties of prostate
tumors, by mechanistically modulating family with
sequence similarity 101 member B (FAM101B), a
transforming growth factor-beta (TGF-β) signaling
effector inducing epithelial-to-mesenchymal transition
(EMT) and organizing the actin cytoskeleton, the scaffold
for integration of membrane and intracellular functions.
The findings are of translational significance enabling new
mechanistic insights into the contribution of this nuclear
spindle player NUSAP1 to prostate cancer cell invasion,
as well as defining its clinical value in predicting prostate
cancer metastasis.
NUSAP1 is a microtubule and chromatin-binding
protein the serves to bind DNA to the mitotic spindle and
facilitate crosslinking of microtubules during mitosis. Its
validation as a prostate cancer correlative marker nonwithstanding, NUSAP1 gene expression is regulated by
a promoter binding site for the transcription factor E2F
and negatively regulated by the tumor suppressor RB1 [3,
www.impactjournals.com/oncotarget

5]. NUSAP1 has been causally linked to cell proliferation
based on its role in the mitotic spindle assembly, but
the insightful functional approaches in the current study
provide compelling evidence on a new role for NUSAP1
in prostate cancer invasion and metastasis. The study
shows that loss of NUSAP1 decreased migration in
androgen-independent prostate cancer cells but had
limited effect on the growth dynamics of prostate cancer
cells in vitro (proliferation, apoptosis). In vivo assessment
of the burden of visceral and nodal metastases in the PC-3
androgen-independent prostate cancer xenograft model,
revealed enhanced metastases consequential to NUSAP1
overexpression, while silencing NUSAP1 reduced
metastasis [4].
Genome wide association data analysis revealed
highest NUSAP1 transcripts in human metastatic lesions.
Microarray analysis showed a common signature of
transcription regulation in genes involved in cancer,
cell injury, survival and death associated with NUSAP1
under- or overexpression. Furthermore, validated pathway
analysis associated this unique signature with tumor
progression and patient survival. FAM101B (RefilinB) acts
as a molecular switch in the organization of perinuclear
actin during EMT [6]. EMT is recognized as a critical
venue for epithelial derived tumors to become invasive
and rapidly metastasize, with loss of epithelial cell
markers and gain of mesenchymal markers at the invasive
front. Significantly enough, FAM101B is upregulated by
the master EMT-inducer in the prostate, TGF-β, and loss

Figure 1: Intracellular NUSAP1 signaling. NUSAP1

expression is promoted by AR and E2F and inhibited by RB1.
In the cytosol, NUSAP1 acts under the direction of TGF-β to
organize the actin cytoskeleton and drive EMT towards invasion
and metastasis of prostate cancer cells. NUSAP1- Nucleolar
and spindle associated protein 1, AR- Androgen receptor,
RB1- Retinoblastoma 1, E2F- E2 factor, FAM101B- Family
with sequence similarity 101 member B, TGF-β- Transforming
growth factor-beta, EMT- Epithelial-to-mesenchymal transition
12544

Oncotarget

of FAM101B reversed the EMT phenotype exhibited in
NUSAP1 overexpressing prostate cancer cells in vitro,
pointing to the functional interaction between the two
players [4].
Elucidation of downstream signaling targets/
effectors of NUSAP1 is currently under mechanistic
pursuit with evidence so far implicating the retinoblastoma
RB1 tumor suppressor as a leading candidate, since the
transcriptional regulation of NUSAP1 expression is
under the control of the well-defined E2F-RB1 pathway
(Figure 1). Thus RB1, loss of which correlates with
prostate cancer virulence, provides a mechanism bridging
upregulation of NUSAP1 to the invasive properties of
prostate cancer cells [5]. Further molecular evidence
indicating an AR binding site upstream of the NUSAP1
transcription start site and NUSAP1 induction in response
to androgens in androgen-sensitive prostate cancer cells
[7], positions the AR as a mechanistic protagonist in the
upregulation of NUSAP1 in metastatic prostate cancer.
Growth stimulation promotes the actin polymerization
assembly to generate movement, via cofilin, a TGF-β
signaling effector recruited to stabilize perinuclear and
cytosolic actin bundles towards an EMT phenotype [8],
thus navigating the actin cytoskeleton polymerization in
prostate cancer cells (Figure 1). Mutational inactivation
of cofilin, significantly compromises prostate cancer
cell adhesion, migration and filpodia formation due to
enhanced polymerization of F-actin filaments [8].
The role of NUSAP1 in regulating microtubule
assembly and stability during mitosis, through its
signaling effector FAM101B, provides new target leads.
Taxane- chemotherapy is a clinically effective treatment
for metastatic CRPC through stabilizing β-tubulin within
the microtubule structure, deregulation of the mitotic
spindle, apoptosis induction and impairing AR activity
[1, 2]. Considering that therapeutic resistance leads to
recurrent disease in CRPC patients [2], NUSAP1 presents
itself at a convergence targeting point, calling for synergy
in action against NUSAP1 in combination with taxane
chemotherapy in CRPC. Support for an optimization
platform is granted from recent evidence that taxaneinduced apoptosis in oral squamous cell carcinoma was
enhanced in the absence of NUSAP1 [9].
With the knowledge that development of castration
resistance is pivotal in the progression to aggressive
disease, it is critical that future investigative efforts focus
on CRPC tumors with diverse AR status that may impact
the effects of NUSAP1 on the dynamics of microtubules
and the actin cytoskeleton towards metastasis. The
preclinical models used in this study were limited by their
inability to capture and characterize the complexity of
the tumor microenvironment during advanced metastatic
progression [4]. Utilization of relevant models of prostate
cancer metastasis will enable biological outcomes as
www.impactjournals.com/oncotarget

to the impact of NUSAP1 on the EMT landscapes and
microtubule stabilization dynamics, ultimately defining
its therapeutic targeting value by combinatorial synergy
of FDA approved agents with new drugs (Figure 1).
Development of a novel inhibitor targeting NUSAP1 and
its nuclear partners, might deliver a personalized therapy
with a promise in the clinical management of patients with
advanced prostate cancer.
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